Notice for Lutetium-177 chloride (non-carrier-added) (ANSTO t/a ANSTO Health)
Active ingredients
Lutetium-177 chloride (non-carrier-added)
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution
Indication
For the treatment of non resectable or metastatic neuroendocrine tumours (NETS) expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule
Therapeutic area
Oncology